Response Biomedical (V.RBM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Response Biomedical (V.RBM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Christopher Millard who started this subject	2/13/2001 2:55:08 PM
From: Dick Martin	Read Replies (1) of 655

FACT SHEET BETA TESTING ON RAMP COMPLETE Þ The preclinical beta study was conducted by doctors, nurses and clinical laboratory technologists at two independent Vancouver sites: CEQAL Inc., Canada’s leading reference method laboratory for clinical labs; and St. Paul’s Hospital. Þ The study confirmed that the RAMP System produces reproducible, quantitative results; is simple to operate; and requires no special training. The study also assures that the RAMP System and myoglobin blood test are ready to proceed to FDA clinical trials in March. Þ Myoglobin is the first of three RAMP cardiac marker tests to be developed. Troponin I and CK-MB are in late stage development. Þ The completion of beta testing on the RAMP System is one of the key components in advancing the Company’s business development relationships. Þ The US market for cardiac marker testing in 2000 was estimated to be US$150 million by Theta Reports (#1045) with approximately 30% or $46 million being point-of-care (POC) testing. Sustained growth rates in the POC sector of 20% to 30% are expected through the year 2005 as the use of the technology becomes more widespread. Þ The American Heart Association (www.amheart.org) and the American College of Cardiology (www.acc.org) guidelines state that patients with suspected acute coronary syndromes must be evaluated rapidly. The guidelines also state that cardiac marker results should be obtained within 30 minutes. Þ The quantitative RAMP myoglobin test uses a small blood sample and can deliver results in less than 10 minutes. Þ Myoglobin is a low- molecular-weight protein found in both cardiac and skeletal muscle and may be detected as early as 2 hours after the onset of myocardial necrosis (heart attack). Due to its high sensitivity, a negative test for myoglobin is useful in ruling out myocardial necrosis. For more information, please contact: Ryan Males, Ph.D. Manager, Corporate Communications Response Biomedical Corp. 604 412-6055 tel 604 412-9830 fax rmales@responsebio.com Joanna Longo, Investor Relations The Equicom Group Inc. 416 815-0700 tel 416 815-0080 fax jlongo@equicomgroup.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next